The present invention relates to a combination for the treatment of cognitive disorders in a patient comprising histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of N-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(1-cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a pharmaceutical composition comprising the said combination and to methods of treating cognitive disorders comprising administering the said combination.
COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS WITH ACETYLCHOLINESTERASE INHIBITORS